Join us at DeviceTalks Boston on May 10-11 to hear how medical device companies are propping open supply lines and ensuring a steady flow of products to customers in a constantly changing world. Sharing best practices is more important than ever because supply chain challenges aren’t expected to diminish post-pandemic. That’s because superstorms, fires, droughts and other extreme […]
coronavirus
Here at MassDevice — medtech's online business journal — we're covering news about the coronavirus (COVID-19) pandemic daily. Here is the latest about coronavirus and the medical device industry, regulatory changes related to the pandemic, new tests for the virus, vaccine development, and much more.
Cue Health, Major League Baseball partner on COVID-19 testing
Cue Health (Nasdaq:HLTH) and Major League Baseball (MLB) announced today that will expand on league-wide COVID-19 testing. Under a national partnership, Cue Health — MLB’s trusted at-home testing solution — will provide MLB clubs as well as the league office with its integrated care platform that includes the portable and reusable Cue Health monitoring system […]
Visby Medical triggers $25.5M contract option with BARDA to develop at-home COVID-19/flu test
Visby Medical announced today that it picked up $25.5 million in government funding to develop an at-home flu/COVID-19 diagnostic. San Jose, California-based Visby executed an option in a contract from the Biomedical Advanced Research and Development Authority (BARDA) on the additional $25.5 million for the development and validation of the at-home combination test. The incremental […]
Medtronic survey says pandemic has negatively impacted those with chronic back and leg pain
Medtronic (NYSE:MDT) today released data from a survey demonstrating several struggles for those with chronic pain during the COVID-19 pandemic. The survey, commissioned by Medtronic and conducted by public opinion research firm The Harris Poll, found that 44% of current chronic back and leg pain sufferers experienced care delays during the COVID-19 pandemic despite 87% […]
Vaxxas licenses COVID-19 vaccine for patch delivery system, expects to finish Phase 1 trial this year
Vaxxas announced today that it was granted an exclusive license for a next-generation COVID-19 vaccine to be used with its delivery patch. Cambridge, Massachusetts-based Vaxxas received the license from The University of Texas at Austin for its HexaPro SARS-CoV-2 spike subunit vaccine. Get the full story at our sister site, Drug Delivery Business News.
Engineered yeast could be a key for more affordable COVID-19 vaccines
Researchers at MIT and Beth Israel Deaconess Medical Center are exploring a yeast-based alternative to RNA vaccines. A new paper highlights a vaccine, which comprises fragments of the SARS-CoV-2 spike protein arrayed on a virus-like particle, that reportedly elicited a strong immune response and protected animals against viral challenge, according to a post on MIT’s […]
Roche says its research-only COVID-19 tests can detect a range of variants, subvariants
Roche announced today that its TIB Molbiol subsidiary has made available testing solutions that can identify a number of COVID-19 variants. Basel, Switzerland-based Roche’s testing offerings can identify the SARS-CoV-2 (the virus causing COVID-19) B.1.1.529 variant and differentiate between the omicron subvariants BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and delta, according to a news release. VirSNiP […]
Pfizer and BioNTech seeking FDA authorization of fourth COVID-19 vaccine dose for older adults
Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) have filed an application to the FDA for Emergency Use Authorization (EUA) for an additional COVID-19 vaccine booster dose in adults 65 years of age and older. The two companies announced yesterday that they have submitted two real-world data sets from Israel while the omicron variant was widespread. Pfizer […]
NIH to study allergic reactions to COVID-19 mRNA vaccine
Researchers from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) are conducting a clinical trial on allergic reactions to mRNA-based COVID-19 vaccines. The single-site trial will enroll up to 100 people between 16 and 69 years old who had an allergic reaction to a first dose of COVID-19 mRNA vaccines. NIAID seeks participants […]
Countries in need will have access to Moderna COVID-19 vaccine tech
Moderna (Nasdaq:MRNA) announced four new initiatives within a global public health strategy for advancing mRNA vaccines. Cambridge, Massachusetts-based Moderna plans to expand its global public health portfolio, accelerate research in an effort to advance additional vaccines, expand its patent pledge to never enforce COVID-19 patents in the Gavi COVAX AMC for 92 low- and middle-income […]
Johnson & Johnson inks agreement to have its COVID-19 vaccine manufactured in Africa
Johnson & Johnson (NYSE:JNJ) announced today that it completed an agreement for the manufacturing of its COVID-19 vaccine in Africa. The landmark agreement, made between Johnson & Johnson’s Janssen Pharmaceuticals and South Africa-based Aspen SA Operations, allows for the first COVID-19 vaccine to be manufactured and made available by an African company for people living in […]